Harnessing Nature To Beat Cancer

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in auto-immune and oncology disease indications. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP) with unique immuno-oncology properties.

Celgene, one of the world’s largest biotechnology companies owns a 12% equity stake in ACT.

News

October 17, 2017

Study Results of ACT-101 in a Model of Inflammatory Bowel Disease (IBD) Presented at the World Congress of Gastroenterology 2017

Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on therapies for patients with autoimmune diseases and cancer, today announced the results of a study of ACT-101 (recombinant human alpha fetoprotein or rhAFP) in the treatment of Inflammatory Bowel Disease (IBD) at the World Congress of Gastroenterology 2017, held in partnership with The American College of Gastroenterology in Orlando, Florida. The study was sponsored by ACT to corroborate published clinical trial results using native human AFP.

Download

June 15, 2017

Alpha Cancer Technologies Inc. Reports Acceptance of the Abstract of Study of ACT-101 in a Model of Inflammatory Bowel Disease to the World Congress of Gastroenterology at ACG 2017

Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that the abstract describing the results of a pre-clinical study of the efficacy of ACT-101 in a mouse model of inflammatory bowel disease (IBD) has been submitted for presentation at the World Congress of Gastroenterology at ACG 2017 to be held in Orlando, Florida October 13-18, 2017.

Download

May 15, 2017

Alpha Cancer Technologies Inc. Announces Presentation of ACT-101 Study Results in Pre-Clinical Model of Myasthenia Gravis (MG) at the 13th International Conference on Myasthenia Gravis and Related Disorders

Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that an abstract highlighting the results of a study of ACT-101 (recombinant human alpha fetoprotein or AFP) in the treatment of myasthenia gravis has been presented at the 13th International Conference on Myasthenia Gravis and Related Disorders held on May 15-17, 2017 in New York. This conference was organized by the Myasthenia Gravis Foundation of America and the New York Academy of Sciences. The study was presented by the principal investigator, by Dr. Linda Kusner of the Laboratory for Myasthenia Gravis Research at George Washington University School of Medicine & Health Sciences.

Download

December 20, 2015

Emerging Health Technologies Can Enhance Canada’s Prosperity

The Canadian Business Journal

Canadian pharmaceutical company Alpha Cancer Technologies Inc. is developing a way to deliver chemotherapy more effectively and with lower doses so the treatment does not cause toxicity in patients.

Read

May 28, 2014

PolyTherics and Alpha Cancer Technologies Collaborate to Produce Novel Drug Conjugates to Target Tumours

Press Release

PolyTherics Limited (“PolyTherics”), an Abzena company that provides technologies and services to enable the development of better biopharmaceuticals, today announced a collaboration with Alpha Cancer Technologies Inc. (“ACT”), a Canadian company with a targeted drug delivery platform based on alpha fetoprotein (“AFP”). PolyTherics will produce a range of AFP drug conjugates for ACT to test using its proprietary ThioBridge™ technology.

Download